The Endocannabinoid System Explained

The endocannabinoid system (ECS) is one of the most significant, most versatile and yet least known regulatory systems of the human body. Discovered only in the 1990s, research into this system has fundamentally changed our understanding of physiology, pharmacology and the mechanism of action of cannabis. The ECS is involved in regulating an astonishing range of bodily functions – from pain perception through immune response to mood, appetite and sleep. This article explains the components, mechanisms and clinical relevance of this fascinating system.

## Discovery History

The history of the endocannabinoid system paradoxically begins with research on the cannabis plant. In 1964, Israeli chemists Raphael Mechoulam and Yechiel Gaoni first isolated delta-9-tetrahydrocannabinol (THC) as the primary psychoactive component of cannabis. But the crucial question remained unanswered: why does the human body possess receptors that respond to a plant-derived substance?

The answer came gradually. In 1988, Allyn Howlett and William Devane discovered the first cannabinoid receptor (CB1) in rat brains. In 1993, Sean Munro identified the second cannabinoid receptor (CB2) in the immune system. The decisive insight followed in 1992, when Mechoulam and his team identified anandamide – the first endogenous substance that binds to CB1 receptors. The name derives from the Sanskrit word ananda (bliss). In 1995, 2-arachidonoylglycerol (2-AG) was discovered as the second endogenous cannabinoid ligand.

These discoveries revealed a fundamental biological principle: the human body produces its own cannabinoid-like substances (endocannabinoids) that bind to specific receptors and form a complex regulatory system. The plant cannabinoids (phytocannabinoids) such as THC and CBD work because they mimic or modulate the structure of these endogenous substances.

## What Are Endocannabinoids?

The term endocannabinoids is composed of endo (Greek for within, endogenous) and cannabinoids (named after the cannabis plant, in which related substances were first discovered). Endocannabinoids are thus endogenous lipid signalling molecules that share structural and functional similarities with plant cannabinoids. They belong to the class of eicosanoids – signalling molecules formed from polyunsaturated fatty acids such as arachidonic acid.

Unlike classical neurotransmitters such as serotonin, dopamine or GABA, endocannabinoids are not stored in synaptic vesicles and released on demand. Instead, they are synthesized on demand directly from membrane components of the cell. This property makes them particularly flexible and rapidly responding signalling molecules that can be precisely tuned to current physiological needs.

## Main Components of the ECS

The endocannabinoid system consists of three main components: cannabinoid receptors, endocannabinoids, and the enzymes responsible for synthesis and degradation of endocannabinoids.

### CB1 Receptors

CB1 receptors are the most abundant G-protein-coupled receptors in the human brain. They are found in particularly high density in the following brain regions:

**Hippocampus:** Centre for memory formation and learning. The high CB1 density in the hippocampus explains the short-term memory effects of cannabis.

**Basal ganglia and cerebellum:** Responsible for movement coordination and motor control. CB1 activation in these regions explains the motor effects of cannabis and the therapeutic potential for movement disorders such as spasticity.

**Prefrontal cortex:** Responsible for decision-making, planning and impulse control. CB1 receptors in this region influence cognitive functions and emotional processing.

**Amygdala:** Centre for emotional processing and fear response. CB1 activation in the amygdala can have anxiolytic effects, explaining the anxiolytic properties of cannabis.

**Hypothalamus:** Regulates hunger, thirst, body temperature and circadian rhythms. CB1 receptors in the hypothalamus are largely responsible for the appetite-stimulating effect of THC.

CB1 receptors are also found outside the brain – in the liver, adipose tissue, gastrointestinal tract and reproductive system. Their functions in these tissues are increasingly being researched and could be relevant for metabolic diseases such as obesity and type 2 diabetes. In the liver, CB1 activation promotes lipogenesis (fat production) and can contribute to the development of fatty liver disease. In adipose tissue, CB1 receptors influence the balance between fat storage and fat burning. The failed weight-loss drug rimonabant (Acomplia), which blocked CB1 receptors and was withdrawn due to psychiatric side effects, illustrates both the therapeutic potential and the risks of manipulating this system.

### CB2 Receptors

CB2 receptors are found predominantly in the immune system – on immune cells such as macrophages, B cells, T cells and natural killer cells, in the spleen, tonsils and bone marrow. Recent research has also detected CB2 receptors in the brain, particularly on microglial cells, where they play a role in neuroinflammatory processes.

Activation of CB2 receptors has predominantly immunomodulatory and anti-inflammatory effects, making them promising therapeutic targets for conditions such as chronic inflammation, autoimmune diseases, neurodegenerative diseases and osteoporosis.

### Additional Receptors

Beyond CB1 and CB2, endocannabinoids interact with further receptors sometimes referred to as the expanded endocannabinoid system (endocannabinoidome):

**TRPV1 (Vanilloid Receptor 1):** This receptor, which also responds to capsaicin, is involved in pain perception. Anandamide activates TRPV1, contributing to pain modulation.

**GPR55:** Discussed by some researchers as a potential CB3 receptor, it may play a role in regulating bone density, blood pressure and cancer growth.

**PPARs (Peroxisome Proliferator-Activated Receptors):** These nuclear receptors are activated by some endocannabinoids and phytocannabinoids and play roles in metabolism and inflammatory processes.

## The Endocannabinoids

### Anandamide (AEA)

Anandamide (arachidonoylethanolamide, AEA) was the first identified endocannabinoid. It binds as a partial agonist to CB1 receptors and more weakly to CB2 receptors. Anandamide is synthesized on demand from membrane phospholipids.

Anandamide plays a central role in mood regulation and well-being, often called the bliss molecule. The so-called runner's high – the euphoria after intense physical exertion, long attributed exclusively to endorphins – is now understood to be substantially mediated by elevated anandamide levels. A 2015 study published in the Proceedings of the National Academy of Sciences showed that mice exhibited elevated anandamide levels after running and that blocking CB1 receptors abolished the runner's high.

### 2-Arachidonoylglycerol (2-AG)

2-AG is the most abundant endocannabinoid in the human body, present in substantially higher concentrations than anandamide. It is a full agonist at both cannabinoid receptors. 2-AG plays a central role in synaptic plasticity through retrograde signalling: when a postsynaptic neuron is activated, it releases 2-AG, which travels backwards to the presynaptic cell and activates CB1 receptors, reducing neurotransmitter release. This mechanism serves as a brake preventing excessive neuronal activity and is fundamental to neuronal homeostasis.

## Enzymatic Degradation: FAAH and MAGL

The action of endocannabinoids is temporally limited by specific enzymes that rapidly degrade them after signalling:

**FAAH (Fatty Acid Amide Hydrolase):** The primary enzyme for anandamide degradation. Genetic variants leading to reduced FAAH activity are associated with increased pain tolerance and decreased anxiety. FAAH inhibitors are being researched as potential medicines for pain, anxiety and inflammation.

**MAGL (Monoacylglycerol Lipase):** The primary enzyme for 2-AG degradation. MAGL inhibitors show anti-inflammatory and analgesic effects in animal studies.

## Functions of the ECS in the Body

### Pain Regulation

The ECS is involved at all levels of pain processing – from peripheral pain perception through spinal transmission to central processing in the brain. CB1 receptors in pain pathways modulate the release of pain signalling molecules, while CB2 receptors on immune cells regulate inflammatory mediators contributing to pain sensitization.

### Immune System

CB2 receptors on immune cells regulate the immune response in multiple ways, influencing cytokine production, cell migration, apoptosis and immune cell differentiation.

### Mood and Emotional Regulation

The ECS plays a central role in emotional regulation. CB1 receptors in the amygdala, prefrontal cortex and hippocampus influence the processing of fear, stress and reward. The ECS mediates fear extinction – the process by which conditioned fear responses are gradually reduced. When a previously feared stimulus is repeatedly presented without negative consequences, the brain must learn that the stimulus is no longer dangerous. This learning process depends critically on endocannabinoid signalling in the amygdala. Impaired fear extinction is a hallmark of post-traumatic stress disorder (PTSD), which is why cannabinoid-based therapies for PTSD are being intensively researched.

Animal studies show that mice without a functioning ECS (CB1 knockout mice) exhibit increased anxiety behaviour, depression-like symptoms and heightened stress susceptibility. These animals also show impaired social behaviour, reduced exploratory activity and deficient stress coping – a pattern strikingly reminiscent of human anxiety and depressive disorders. In humans, reduced anandamide levels have been demonstrated in patients with PTSD, depression and anxiety disorders. A 2014 study in the journal Biological Psychiatry found that individuals with PTSD had significantly lower circulating anandamide levels than healthy controls, and that these levels correlated inversely with symptom severity.

The therapeutic implications are significant: enhancing endocannabinoid signalling – whether through exogenous cannabinoids, FAAH inhibitors or lifestyle interventions – could represent a novel approach to treating anxiety and mood disorders.

### Appetite and Metabolism

THC's appetite-stimulating effect – colloquially known as the munchies – results from activation of CB1 receptors in the hypothalamus and mesolimbic reward system. The ECS regulates not only appetite but overall energy balance, with CB1 receptors in the liver influencing glucose production and fat metabolism, and CB1 receptors in adipose tissue controlling fat storage.

### Bone Health

A lesser-known aspect of the ECS is its role in bone metabolism. CB2 receptors are found on osteoblasts (bone-forming cells), osteoclasts (bone-resorbing cells) and osteocytes. Activation of CB2 receptors promotes bone formation and inhibits bone resorption, making the ECS a potential therapeutic target in osteoporosis. Animal studies show that CB2 agonists can slow age-related bone density loss.

### Reproduction and Fertility

The ECS plays a surprisingly important role in reproductive physiology. CB1 and CB2 receptors are found in the ovaries, uterus, testes and placenta. Endocannabinoids influence the menstrual cycle, oocyte maturation, sperm quality and embryo implantation. Anandamide plays a demonstrated role in the so-called implantation window – the brief period during which the uterine lining is receptive to a fertilized egg.

### Skin and External Barriers

The skin possesses its own functional endocannabinoid system. Keratinocytes, sebocytes, melanocytes and hair follicle cells express cannabinoid receptors and produce endocannabinoids. The cutaneous ECS regulates cell proliferation, sebum production, melanin production and the inflammatory immune response of the skin.

### Sleep

The ECS is involved in regulating the sleep-wake cycle. Anandamide promotes sleep by dampening the activity of wakefulness-promoting neuronal populations. THC shortens sleep onset latency and may extend total sleep time but reduces the REM sleep proportion. CBD appears to promote wakefulness at low doses and sleep at higher doses.

### Sleep

The ECS is involved in regulating the sleep-wake cycle. Anandamide promotes sleep by dampening the activity of wakefulness-promoting neuronal populations. CB1 receptors in the hypothalamus and brainstem modulate circadian rhythms and sleep architecture. THC shortens sleep onset latency and may extend total sleep time but reduces the REM sleep proportion. CBD appears to promote wakefulness at low doses and sleep at higher doses. The optimal use of cannabinoids for sleep therapy requires a better understanding of these dose-dependent effects.

## Clinical Relevance: Endocannabinoid Deficiency

American neurologist Ethan Russo postulated in 2001 the theory of Clinical Endocannabinoid Deficiency (CED). According to this hypothesis, certain conditions – particularly migraine, fibromyalgia and irritable bowel syndrome – may be attributable to insufficient endocannabinoid production or signalling. This theory is supported by the observation that these three conditions frequently co-occur, often respond poorly to conventional therapies, and may benefit from cannabinoid-based therapies.

More recent research has provided additional support for the CED hypothesis. A 2016 study found that women with migraine had reduced levels of anandamide in their cerebrospinal fluid compared to healthy controls. Patients with fibromyalgia show altered expression patterns of cannabinoid receptors in their skin tissue. These findings, while not conclusive proof, are consistent with the idea that an underactive endocannabinoid system contributes to these conditions.

## The ECS as a Therapeutic Target

The endocannabinoid system offers numerous points of intervention for therapeutic approaches: direct receptor agonists, enzyme inhibitors (FAAH and MAGL inhibitors), allosteric modulators, and endocannabinoid transport inhibitors. The future of endocannabinoid research lies in developing targeted, low-side-effect medicines that modulate the ECS without triggering the broad effects of THC.

## Epigenetics and the Endocannabinoid System

An emerging research area concerns the interactions between the ECS and epigenetic mechanisms. Epigenetic changes – chemical modifications of DNA that influence gene expression without altering the DNA sequence itself – can be influenced by cannabinoid exposure. Animal studies have shown that chronic THC consumption can alter DNA methylation patterns in certain brain regions, potentially influencing the expression of genes involved in synaptic plasticity, stress response and reward processing.

Particularly contentious is the question of transgenerational effects: can epigenetic changes caused by cannabis use be passed on to offspring? Animal data suggest this may be possible – male rats exposed to THC before conception produced offspring with altered endocannabinoid signalling pathways. However, these findings are preliminary and cannot be directly extrapolated to humans.

## The ECS Across the Lifespan

The function of the endocannabinoid system changes considerably over the course of life. In prenatal development, the ECS plays a critical role in directing neuronal migration, axon growth and synapse formation. CB1 receptors are detectable early in embryonic development and guide the correct wiring of nerve cells. This explains why prenatal cannabis exposure can potentially influence brain development.

In adolescence, the ECS undergoes a phase of reorganization that accompanies comprehensive brain maturation. The endocannabinoid tone in the prefrontal cortex changes during puberty, which may explain this age group's vulnerability to external cannabinoids. Research suggests that disruption of the ECS during this sensitive phase can have longer-lasting consequences than in adulthood.

In old age, CB1 receptor density decreases in certain brain regions, correlating with cognitive changes and altered pain perception. Interestingly, animal studies show that low-dose THC can improve cognitive functions in older mice – a paradoxical effect not observed in young animals. These findings have sparked speculation about potential therapeutic use of cannabinoids for age-related cognitive decline.

## Nutrition, Lifestyle and the ECS

The endocannabinoid system is influenced not only by cannabinoids but also by nutrition and lifestyle. Omega-3 fatty acids found in fatty fish, flaxseed and walnuts are precursor substances for endocannabinoid synthesis. A diet rich in omega-3 fatty acids can positively influence endocannabinoid tone.

Physical exercise is one of the strongest natural modulators of the ECS. As mentioned, anandamide levels rise significantly after intense physical exertion. Regular exercise improves CB1 receptor sensitivity and normalizes endocannabinoid tone. This may be a mechanism through which exercise exerts antidepressant, anxiolytic and pain-relieving effects.

Chronic stress, conversely, can dysregulate the ECS. Stress hormones like cortisol influence endocannabinoid production and receptor expression. Chronic stress typically leads to downregulation of the ECS, increasing susceptibility to anxiety, depression and chronic pain. Stress-reducing measures – meditation, yoga, social bonding – can improve ECS function.

Certain foods also contain substances that modulate the ECS. Chocolate contains anandamide and anandamide-like substances as well as FAAH inhibitors that slow anandamide degradation. Black pepper contains beta-caryophyllene, a terpene that acts as a selective CB2 agonist. Truffles contain anandamide. Even human breast milk contains 2-AG, which may play a role in stimulating the suckling reflex in newborns. These connections demonstrate that the ECS is embedded in a broader network of physiological regulatory mechanisms.

## The ECS and the Gut-Brain Axis

One of the most exciting recent developments in ECS research concerns the gut-brain axis – the bidirectional communication system between the gastrointestinal tract and the central nervous system. The gut possesses an extensive endocannabinoid system, with both CB1 and CB2 receptors distributed throughout the intestinal lining, the enteric nervous system and the gut-associated immune tissue. Endocannabinoids in the gut regulate intestinal motility, gastric acid secretion, inflammation and the permeability of the intestinal barrier.

Emerging research suggests that the gut microbiome – the trillions of bacteria living in the intestinal tract – can influence the endocannabinoid system and vice versa. Certain gut bacteria produce molecules that interact with cannabinoid receptors, and endocannabinoid signalling influences the composition of the microbiome. This bidirectional interaction could be relevant for conditions such as irritable bowel syndrome, inflammatory bowel disease and even psychiatric disorders, given the well-established connection between gut health and mental health.

A 2020 study published in Nature Medicine found that mice with a depleted microbiome showed reduced endocannabinoid signalling in the brain, along with increased anxiety-like behaviour. Restoring the microbiome normalized both endocannabinoid levels and behaviour. While these animal findings cannot be directly translated to humans, they highlight the fascinating interconnection between gut health, the ECS and brain function.

## Practical Implications: What Does This Mean for Cannabis Users?

Understanding the endocannabinoid system has important practical implications for both medical and recreational cannabis users. First, it explains why cannabis affects different people differently: individual variations in receptor density, endocannabinoid production and enzyme activity create a unique endocannabinoid profile for each person. This is why the same cannabis dose can produce relaxation in one person and anxiety in another.

Second, it underscores the importance of dosing. Because cannabis interacts with a finely tuned regulatory system, low doses may support the system's function while high doses can overwhelm it. The concept of "less is more" – increasingly recognised in cannabinoid medicine – reflects this understanding.

Third, it suggests that a healthy lifestyle – including regular exercise, a balanced diet rich in omega-3 fatty acids, adequate sleep and stress management – can optimise the functioning of the endocannabinoid system and potentially reduce the need for exogenous cannabinoids.